Creative Proteomics specializes in advanced proteomics, metabolomics, glycomics, and lipidomics services aimed at pharmaceutical and biotechnology organizations, as well as academic institutions. The company utilizes cutting-edge technology platforms, such as mass spectrometry and chromatography, to ensure accurate and reliable results for their clients. The company's core strength lies in offering comprehensive omics analysis services to support drug discovery, biomarker identification, and molecular mechanism research across multiple scientific disciplines.
Cyborg Score Rationale
Creative Proteomics is a stable, established services company with a 20+ year track record since inception in 2005, offering essential scientific research services to a diverse global clientele. However, growth appears modest relative to better-funded competitors, with inconsistent employee count reporting and limited recent market momentum indicators, suggesting a mature but not rapidly scaling operation.
Top Insights
Founded in 2005 and headquartered in Shirley, NY, Creative Proteomics has established itself as a long-standing provider of specialized analytical services
Launched Comprehensive Ames Test Service in January 2025 to enhance mutagenicity testing, expanding its regulatory support offerings for drug development
Offers an extensive range of scientific analysis services, including protein modification analysis, metabolite profiling, and customized synthetic peptides
The company operates globally with strong geographic reach but competes in a fragmented market against well-funded specialized biotech service providers
Named Competitors
Parexel International — Integrated CRO offering drug development and consulting services
Patheon — Integrated CRO and pharmaceutical services provider
NanoImaging Services — Molecular imaging and characterization services
Syrrx — Structural biology and protein characterization
Beryllium — Drug discovery and development support services
Recent Developments
(January 2025) Launched Comprehensive Ames Test Service for mutagenicity testing in drug development
(March 2026) Posted educational content on lipidomics analysis and host cell protein testing
Service expansion into precision metabolomics and advanced coenzyme A analysis for biomarker research
Open the full interactive Creative Proteomics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.